Evidence map›Paper›PMID 28406488›Full record

ReviewGenetics in medicine : official journal of the American College of Medical Genetics2017

Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.

Kathryn A Phillips, Patricia A Deverka, Harold C Sox, Muin J Khoury, Lewis G Sandy, Geoffrey S Ginsburg, Sean R Tunis, Lori A Orlando, Michael P Douglas

Registry-linked trialAbstract readReview
In one paragraph

Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04331535 (Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04331535 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care

TypeinterventionalSponsorBoston VA Research Institute, Inc.Ran2020 to 2025Enrolled1,076ConditionsCoronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal CancerArmsPolygenic risk score (PRS)
3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Using the Delphi method to identify clinicians' perceived importance of pediatric exome sequencing results.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  9. Review
  10. Review
  11. Article
  12. Rapid Whole Genome Sequencing Has Clinical Utility in Children in the PICU.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2019
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  18. Genome-wide sequencing in acutely ill infants: genomic medicine's critical application?Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  19. Infectious Disease Risk in Dialysis Patients: A Transdisciplinary Approach.Canadian journal of kidney health and disease · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathryn A PhillipsDepartment of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), UCSF Philip R. Lee Institute for Health Policy and UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California, USA.
Patricia A DeverkaAmerican Institutes for Research, Chapel Hill, North Carolina, USA.
Harold C SoxPatient-Centered Outcomes Research Institute, Washington, DC, USA.
Muin J KhouryOffice of Public Health Genomics, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-9887-443X
Lewis G SandyUnitedHealth Group, Minnetonka, Minnesota, USA.
Geoffrey S GinsburgDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Sean R TunisCenter for Medical Technology Policy, Baltimore, Maryland, USA.
Lori A OrlandoDivision of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.ORCID 0000-0003-2534-7855
Michael P DouglasUniversity of California at San Francisco, Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), San Francisco, California, USA.ORCID 0000-0001-8517-6678

Funding

UTILIZATION OF PERSONALIZED MEDICINE USING GENOMICSP01CA130818 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2008 to 2010
$5.1M
Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5M
NCI NIH HHS P01 CA130818NHGRI NIH HHS R01 HG007063
6 · The paper itself

Abstract

Comparative effectiveness research (CER) in genomic medicine (GM) measures the clinical utility of using genomic information to guide clinical care in comparison to appropriate alternatives. We summarized findings of high-quality systematic reviews that compared the analytic and clinical validity and clinical utility of GM tests. We focused on clinical utility findings to summarize CER-derived evidence about GM and identify evidence gaps and future research needs. We abstracted key elements of study design, GM interventions, results, and study quality ratings from 21 systematic reviews published in 2010 through 2015. More than half (N = 13) of the reviews were of cancer-related tests. All reviews identified potentially important clinical applications of the GM interventions, but most had significant methodological weaknesses that largely precluded any conclusions about clinical utility. Twelve reviews discussed the importance of patient-centered outcomes, although few described evidence about the impact of genomic medicine on these outcomes. In summary, we found a very limited body of evidence about the effect of using genomic tests on health outcomes and many evidence gaps for CER to address.Genet Med advance online publication 13 April 2017.

Indexed as

Comparative Effectiveness ResearchEvidence-Based MedicineHumansOutcome Assessment, Health CarePrecision MedicineResearch Design

Identifiers

PMID28406488
PMCPMC5629101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.